News & Progress
Press Releases
-
June 09, 2021
Palleon Pharmaceuticals Appoints David Feltquate as Chief Medical Officer -
April 09, 2021
Palleon Pharmaceuticals Presents Data Suggesting Role of Hypersialylation in Metastatic Melanoma Patients’ Resistance to PD1 Inhibitors -
February 08, 2021
Palleon Pharmaceuticals Appoints Nikola Trbovic to its Board of Directors -
December 04, 2020
Palleon Pharmaceuticals Appoints Deepa Pakianathan, Ph.D., to its Board of Directors
In the News
-
September 17, 2020
With details on lead sialoglycan degrader in place, Palleon raises $100M series B
BioCentury -
Palleon battalion bags $100M series B for glycan push
BioWorld -
Palleon Pharmaceuticals secures $100m in Series B funding
Pharmaceutical Technology -
Jim Broderick reels in a $100M Series B to explore a ‘new and big’ angle of immune regulation
Endpoints
Publications & Posters
- Poster
Melanoma patients with multi-Siglec ligands as profiled by HYDRA technology are refractory to PD1 blockade
American Association for Cancer Research Annual Meeting, April 10, 2021, Poster #491 - Poster
HYDRA Platform Development to Investigate Siglec-engaging Tumor Immunosuppressive Glyco-codes
Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting, November 9, 2019, Abstract #P118 - Poster
Blockade of Siglec/Sialoglycan Axis Using EAGLE Technology to Potentiate Anticancer Immunity
Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting, November 8, 2019, Abstract #P273 - Publication
Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment
Cancer Immunology Research. April 23, 2019.
@Palleon_Pharma • Jul 26, 2021
Our #PalleonPeople are pretty sweet! Check out some of our team’s go-to desserts. http://6Vvf8P6dMg
@Palleon_Pharma • Jul 23, 2021
We are happy to welcome the newest member of our team, Matt Iorio! Matt is Palleon’s corporate controller and a wel… http://sowUCmCBYt